|Bid||9.35 x 60000|
|Ask||9.72 x 60000|
|Day's Range||9.25 - 9.45|
|52 Week Range||2.59 - 9.54|
|Beta (3Y Monthly)||0.77|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The Los Angeles-based company said it had a loss of 24 cents per share. Losses, adjusted for one-time gains and costs, came to 14 cents per share. The digital ad exchange operator posted revenue of $32.4 ...
This is a nice win for this razor and razor-blade concern and helped drive a 15% rally in T2 Biosystems on Thursday. This trial combined the use of TG Therapeutics' compounds TG-1101 and TGR-1202 and Imbruvica to treat chronic lymphocytic leukemia or small lymphocytic lymphoma. After the bell Thursday, TG Therapeutics took advantage of the rally in the stock to initiate a raise of capital.
The Rubicon Project (RUBI) delivered earnings and revenue surprises of 21.74% and 2.76%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Los Angeles-based company said it had a loss of 27 cents. Losses, adjusted for non-recurring costs, came to 18 cents per share. The digital ad exchange operator posted revenue ...
The Rubicon Project (RUBI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
If you’re interested in the Rubicon Project Inc (NYSE:RUBI), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stockRead More...